Michael Bonney Biography and Net Worth



Former Executive Chair of Alnylam, and former Executive Chair and Chief Executive Officer of Kaleido Biosciences; former Board Chair of Magenta Therapeutics; former Director of Bristol Myers Squibb Company; former Chief Executive Officer and Director of Cubist Pharmaceuticals; and former Director of Sarepta Therapeutics and Syros Pharmaceuticals.

What is Michael W. Bonney's net worth?

The estimated net worth of Michael W. Bonney is at least $2.31 million as of December 27th, 2023. Mr. Bonney owns 16,029 shares of Alnylam Pharmaceuticals stock worth more than $2,314,748 as of April 21st. This net worth estimate does not reflect any other investments that Mr. Bonney may own. Learn More about Michael W. Bonney's net worth.

How do I contact Michael W. Bonney?

The corporate mailing address for Mr. Bonney and other Alnylam Pharmaceuticals executives is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. Alnylam Pharmaceuticals can also be reached via phone at (617) 551-8200 and via email at [email protected]. Learn More on Michael W. Bonney's contact information.

Has Michael W. Bonney been buying or selling shares of Alnylam Pharmaceuticals?

Michael W. Bonney has not been actively trading shares of Alnylam Pharmaceuticals during the past quarter. Most recently, Michael W. Bonney sold 30,000 shares of the business's stock in a transaction on Wednesday, December 27th. The shares were sold at an average price of $195.00, for a transaction totalling $5,850,000.00. Following the completion of the sale, the director now directly owns 16,029 shares of the company's stock, valued at $3,125,655. Learn More on Michael W. Bonney's trading history.

Who are Alnylam Pharmaceuticals' active insiders?

Alnylam Pharmaceuticals' insider roster includes Michael Bonney (Director), Jeffrey Dunn (CEO), Indrani Franchini (EVP), Pushkal Garg (CMO), Yvonne Greenstreet (COO), Laurie Keating (EVP), John Maraganore (CEO), Steven Paul (Director), Jeffrey Poulton (CFO), Phillip Sharp (Director), Tolga Tanguler (EVP), and Akshay Vaishnaw (Insider). Learn More on Alnylam Pharmaceuticals' active insiders.

Are insiders buying or selling shares of Alnylam Pharmaceuticals?

In the last year, insiders at the biopharmaceutical company sold shares 10 times. They sold a total of 59,443 shares worth more than $11,438,789.45. The most recent insider tranaction occured on December, 27th when Director Michael W Bonney sold 30,000 shares worth more than $5,850,000.00. Insiders at Alnylam Pharmaceuticals own 1.5% of the company. Learn More about insider trades at Alnylam Pharmaceuticals.

Information on this page was last updated on 12/27/2023.

Michael W. Bonney Insider Trading History at Alnylam Pharmaceuticals

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/27/2023Sell30,000$195.00$5,850,000.0016,029View SEC Filing Icon  
3/9/2016Buy2,000$58.36$116,720.00View SEC Filing Icon  
5/12/2015Buy2,000$112.16$224,320.00View SEC Filing Icon  
See Full Table

Michael W. Bonney Buying and Selling Activity at Alnylam Pharmaceuticals

This chart shows Michael W Bonney's buying and selling at Alnylam Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Alnylam Pharmaceuticals Company Overview

Alnylam Pharmaceuticals logo
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $144.41
Low: $143.50
High: $146.92

50 Day Range

MA: $151.56
Low: $144.41
High: $169.34

2 Week Range

Now: $144.41
Low: $143.50
High: $218.88

Volume

703,168 shs

Average Volume

506,095 shs

Market Capitalization

$18.19 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.39